The member of the Political Bureau of the Party and general director of the CIGB, Doctor of Science Marta Ayala Ávila, clarified that efficacy should not be confused with effectiveness, since the former is determined as part of clinical studies, that is, under ideal research conditions ; while effectiveness is analyzed in real life circumstances
Last July, the Cuban regulatory authority granted Abdala the Authorization of Emergency Use (AUE), after showing an efficacy of 92.28% in the prevention of symptomatic disease, during phase III of clinical trials.
The Abdala vaccine, developed by the Center for Genetic Engineering and Biotechnology (CIGB), has shown 90% effectiveness in severe COVID-19 patients, even with the circulation of the very aggressive Delta variant of the SARS coronavirus. COV-2.
This was made known on Twitter, by the scientific institution that created the drug, which in July received, by the Cuban regulatory authority, the Emergency Use Authorization; after demonstrating an efficacy of 92.28% in the prevention of symptomatic disease, during phase III of clinical trials carried out in the provinces of Granma, Santiago de Cuba and Guantánamo, with more than 40,000 volunteers.
The member of the Political Bureau of the Party and general director of the CIGB, Doctor of Science Marta Ayala Ávila, clarified that efficacy should not be confused with effectiveness, since the former is determined in the setting of clinical studies, that is, under ideal conditions research; while effectiveness is analyzed in real life circumstances.
Among the clinical trials, the intervention study, the health intervention in risk groups and territories, and mass vaccination, more than 14 million doses of this immunogen have been administered in the country.
In recent days, scientists from the CIGB and the Finlay Vaccine Institute (the institution that created Soberana 02 and Soberana Plus) together with BioCubaFarma authorities, presented, before representatives of the World Health Organization, the data of the research carried out to create, produce, test and apply these national drugs against COVID-19, so that they are recognized by the global health entity.
Available in Granma | Author: National Newsroom | internet@granma.cu | September 21, 2021 1:09:25 PM
comments on